GleamWall
中文EN

PHAR Pharming Group N.V. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1828316 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY26.6%
TTM net income YoY124.1%
TTM EPS YoY122.2%
Revenue 3-yr CAGR22.3%
Net income 3-yr CAGR-40.7%

Margins

Gross margin87.9%
Operating margin6.9%
Net margin0.8%
FCF margin14.3%
EBITDA margin—

Returns

ROE1.1%
ROA0.6%
ROIC (approx.)8.7%
Asset turnover0.84x

Leverage & solvency

Liabilities / assets44.6%
Debt / equity0.00x
Current ratio2.59x
Interest coverage131.85x

Cash quality & payout

Operating cash flow / net income19.19x
Accruals ratio-11.5%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$376.13M$297.20M
Cost of revenue$45.50M$35.40M
Gross profit$330.63M$261.80M
R&D expense$100.37M$83.15M
SG&A expense$79.96M$70.65M
Operating income$25.84M-$8.62M
Interest expense$196,000$56,000
Pretax income$12.85M-$8.49M
Income tax$10.31M$3.35M
Net income$2.85M-$11.84M
EPS (basic)0.00-0.02
EPS (diluted)0.00-0.02
Weighted avg. shares (diluted)746.87M785.41M
Balance sheet
Cash & equivalents$145.31M$54.94M
Receivables$54.70M$54.82M
Inventory$64.90M$55.72M
Current assets$299.47M$278.44M
PP&E, netmay include right-of-use assets (IFRS)$7.23M$7.75M
Intangibles$135.54M$61.04M
Total assets$499.96M$399.99M
Current liabilities$115.79M$73.80M
Total liabilities$222.86M$178.92M
Shareholders' equity$277.10M$221.06M
Shares outstanding701.68M680.31M
Cash flow statement
Operating cash flow$54.71M-$1.79M
Capital expenditure$749,000$790,000
Free cash flow$53.96M-$2.58M
Investing cash flow$26.25M$31.62M
Financing cash flow$1.50M-$34.41M
Stock-based compensation$13.77M$11.25M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.